Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 313

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Nuclear EGFR contributes to acquired resistance to cetuximab

Open access
Li, C, Iida, M, Dunn, E F, Ghia, A J, Wheeler, D L·2009·Oncogene

Abstract

Epidermal growth factor receptor (EGFR) is a ubiquitously expressed receptor tyrosine kinase involved in the etiology of several human cancers. Cetuximab is an EGFR-blocking antibody that has been approved for the treatment of patients with head and neck squamous cell carcinoma and metastatic colorectal cancer. Previous reports have shown that EGFR translocation to the nucleus is associated with cell proliferation. Here we investigated mechanisms of acquired resistance to cetuximab using a model derived from the non-small cell lung cancer line H226. We demonstrated that cetuximab-resistant cells overexpress HER family ligands including epidermal growth factor (EGF), amphiregulin, heparin-binding EGF and β-cellulin. Overexpression of these ligands is associated with the nuclear translocation of the EGFR and this process was mediated by the Src family kinases (SFK). Treatment of cetuximab-resistant cells with the SFK inhibitor, dasatinib, resulted in loss of nuclear EGFR, increased membrane expression of the EGFR and resensitization to cetuximab. In addition, expression of a nuclear localization sequence-tagged EGFR in cetuximab-sensitive cells increased resistance to cetuximab both in vitro and in mouse xenografts. Collectively, these data suggest that nuclear expression of EGFR may be an important molecular determinant of resistance to cetuximab therapy and provides a rationale for investigating nuclear EGFR as a biomarker for cetuximab response. Further, these data suggest a rationale for the design of clinical trials that examine the value of treating patients with cetuximab-resistant tumors with inhibitors of SFKs in combination with cetuximab.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/onc.2009.234

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 40

  1. Arteaga CL . (2003). EGF receptor as a therapeutic target: patient selection and mechanisms of resistance to receptor-targeted drugs. J Clin Oncol 21: 289s–2291s. · doi:10.1200/jco.2003.10.523
  2. Bandyopadhyay D, Mandal M, Adam L, Mendelsohn J, Kumar R . (1998). Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells. J Biol Chem 273: 1568–1573. · DOI · Paper page
  3. Bianco R, Troiani T, Tortora G, Ciardiello F . (2005). Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy. Endocr Relat Cancer 12: S159–S171. · DOI
  4. Borrell-Pagès M, Rojo F, Albanell J, Baselga J, Arribas J . (2003). TACE is required for the activation of the EGFR by TGF-alpha in tumors. EMBO J 22: 1114–1124. · DOI · Paper page
  5. Camp ER, Summy J, Bauer TW, Liu W, Gallick GE, Ellis LM . (2005). Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res 11: 397–405. · DOI · Paper page
  6. Cao H, Lei ZM, Bian L, Rao CV . (1995). Functional nuclear epidermal growth factor receptors in human choriocarcinoma JEG-3 cells and normal human placenta. Endocrinology 136: 3163–3172. · DOI
  7. Dittmann K, Mayer C, Fehrenbacher B, Schaller M, Raju U, Milas L et al. (2005). Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem 280: 31182–31189. · DOI · Paper page
  8. Friedmann BJ, Caplin M, Savic B, Shah T, Lord CJ, Ashworth A et al. (2006). Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment. Mol Cancer Ther 5: 209–218. · DOI
  9. Giri DK, Ali-Seyed M, Li LY, Lee DF, Ling P, Bartholomeusz G et al. (2005). Endosomal transport of ErbB-2: mechanism for nuclear entry of the cell surface receptor. Mol Cell Biol 25: 11005–11018. · DOI · Paper page
  10. Gupta AK, McKenna WG, Weber CN, Feldman MD, Goldsmith JD, Mick R et al. (2002). Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res 8: 885–892.
  11. Hanada N, Lo HW, Day CP, Pan Y, Nakajima Y, Hung MC . (2006). Co-regulation of B-Myb expression by E2F1 and EGF receptor. Mol Carcinog 45: 10–17. · DOI · Paper page
  12. Hsu SC, Hung MC . (2007). Characterization of a novel tripartite nuclear localization sequence in the EGFR family. J Biol Chem 282: 10432–10440. · DOI · Paper page
  13. Hung LY, Tseng JT, Lee YC, Xia W, Wang YN, Wu ML et al. (2008). Nuclear epidermal growth factor receptor (EGFR) interacts with signal transducer and activator of transcription 5 (STAT5) in activating Aurora-A gene expression. Nucleic Acids Res 36: 4337–4351. · DOI · Paper page
  14. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M et al. (2005). EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786–792. · DOI · Paper page
  15. Liao HJ, Carpenter G . (2007). Role of the Sec61 translocon in EGF receptor trafficking to the nucleus and gene expression. Mol Biol Cell 18: 1064–1072. · DOI · Paper page
  16. Lin SY, Makino K, Xia W, Matin A, Wen Y, Kwong KY et al. (2001). Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 3: 802–808. · DOI · Paper page
  17. Lo HW, Ali-Seyed M, Wu Y, Bartholomeusz G, Hsu SC, Hung MC . (2006a). Nuclear-cytoplasmic transport of EGFR involves receptor endocytosis, importin beta1 and CRM1. J Cell Biochem 98: 1570–1583. · DOI · Paper page
  18. Lo HW, Hsu SC, Ali-Seyed M, Gunduz M, Xia W, Wei Y et al. (2005a). Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell 7: 575–589. · DOI · Paper page
  19. Lo HW, Hsu SC, Hung MC . (2006b). EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization. Breast Cancer Res Treat 95: 211–218. · DOI · Paper page
  20. Lo HW, Hung MC . (2006). Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival. Br J Cancer 94: 184–188. · DOI · Paper page
  21. Lo HW, Xia W, Wei Y, Ali-Seyed M, Huang SF, Hung MC . (2005b). Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Cancer Res 65: 338–348. · DOI · Paper page
  22. Lu Y, Li X, Liang K, Luwor R, Siddik ZH, Mills GB et al. (2007). Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab. Cancer Res 67: 8240–8247. · DOI · Paper page
  23. Marti U, Burwen SJ, Wells A, Barker ME, Huling S, Feren AM et al. (1991). Localization of epidermal growth factor receptor in hepatocyte nuclei. Hepatology 13: 15–20. · DOI
  24. Massie C, Mills IG . (2006). The developing role of receptors and adaptors. Nat Rev Cancer 6: 403–409. · DOI
  25. Mukohara T, Engelman JA, Hanna NH, Yeap BY, Kobayashi S, Lindeman N et al. (2005). Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst 97: 1185–1194. · DOI · Paper page
  26. Ni CY, Murphy MP, Golde TE, Carpenter G . (2001). gamma-Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 294: 2179–2181. · DOI · Paper page
  27. Offterdinger M, Schofer C, Weipoltshammer K, Grunt TW . (2002). c-erbB-3: a nuclear protein in mammary epithelial cells. J Cell Biol 157: 929–939. · DOI · Paper page
  28. Psyrri A, Egleston B, Weinberger P, Yu Z, Kowalski D, Sasaki C et al. (2008). Correlates and determinants of nuclear epidermal growth factor receptor content in an oropharyngeal cancer tissue microarray. Cancer Epidemiol Biomarkers Prev 17: 1486–1492. · DOI
  29. Psyrri A, Yu Z, Weinberger PM, Sasaki C, Haffty B, Camp R et al. (2005). Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin Cancer Res 11: 5856–5862. · DOI · Paper page
  30. Rajput A, Koterba AP, Kreisberg JI, Foster JM, Willson JK, Brattain MG . (2007). A novel mechanism of resistance to epidermal growth factor receptor antagonism in vivo. Cancer Res 67: 665–673. · DOI
  31. Ritter CA, Perez-Torres M, Rinehart C, Guix M, Dugger T, Engelman JA et al. (2007). Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 13: 4909–4919. · DOI · Paper page
  32. Sunnarborg SW, Hinkle CL, Stevenson M, Russell WE, Raska CS, Peschon JJ et al. (2002). Tumor necrosis factor-alpha converting enzyme (TACE) regulates epidermal growth factor receptor ligand availability. J Biol Chem 277: 12838–12845. · DOI · Paper page
  33. Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM et al. (2001). Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 61: 5090–5101.
  34. Viloria-Petit AM, Kerbel RS . (2004). Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies. Int J Radiat Oncol Biol Phys 58: 914–926. · DOI
  35. Wang SC, Lien HC, Xia W, Chen IF, Lo HW, Wang Z et al. (2004). Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell 6: 251–261. · DOI · Paper page
  36. Wang SC, Nakajima Y, Yu YL, Xia W, Chen CT, Yang CC et al. (2006). Tyrosine phosphorylation controls PCNA function through protein stability. Nat Cell Biol 8: 1359–1368. · DOI · Paper page
  37. Wheeler DL, Iida M, Kruser TJ, Nechrebecki MM, Dunn EF, Armstrong EA et al. (2009). Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab. Cancer Biol Ther 8: 696–703. · DOI · Paper page
  38. Xia W, Wei Y, Du Y, Liu J, Chang B, Yu YL et al. (2009). Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer. Mol Carcinog 48: 610–617. · DOI
  39. Xie Y, Hung MC . (1994). Nuclear localization of p185neu tyrosine kinase and its association with transcriptional transactivation. Biochem Biophys Res Commun 203: 1589–1598. · DOI
  40. Yarden Y, Sliwkowski MX . (2001). Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127–137. · DOI · Paper page

Cited by

See all 313

Metadata

Authors
Li, C., Iida, M., Dunn, E. F., Ghia, A. J., & Wheeler, D. L.
Venue
Oncogene
Published
2009-08-17
Volume
28
Issue
43
Pages
3801-3813
ISSN
  • 0950-9232 (ISSN-L)
  • 1476-5594
OpenAlex
W1996275566
Cited by
313
References
2
FWCI
12.98
Type
journal article
Language
en
Open access
green
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nuclear EGFR contributes to acquired resistance to cetuximab. https://app.cochat.ai/papers/10.1038/onc.2009.234
The paper
Li, C., Iida, M., Dunn, E. F., Ghia, A. J., & Wheeler, D. L. (2009). Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene. https://doi.org/10.1038/onc.2009.234

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.